Both in Biotechnology
Denali Therapeutics vs Vericel
Over the past year DNLI returned +15.6% and VCEL returned +16.6%; their daily moves had a correlation of 0.32.
DNLI +15.6% VCEL +16.6%Growth of $1, one year, split-adjusted
| Metric | DNLI | VCEL |
|---|---|---|
| Price | $18.94 | $40.26 |
| Market cap | $3.03B | $2.06B |
| Today | −1.97% | −6.18% |
| 1 month | −7.7% | +2.1% |
| 6 months | +3.5% | +13.2% |
| Year to date | +14.7% | +11.8% |
| 1 year | +16.6% | +15.4% |
| Revenue growth (YoY) | — | +22.5% |
| Gross margin | 97.4% | 72.8% |
| Net margin | −3539.2% | 2.8% |
| P/E (TTM) | — | 85.1× |
| Price / sales | 840.0× | 6.7× |
| Net cash | $705.0M | $162.5M |
| Dividend yield | — | — |
| Volatility (60d) | 37.4% | 33.0% |
| Short % of float | 11.6% | 11.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).